SAG
TSHA icon

SageView Advisory Group’s Taysha Gene Therapies TSHA Stock Holding History

SageView Advisory Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$270 Buy
+49
New +$238 ﹤0.01% 2499

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SageView Advisory Group's TSHA Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Taysha Gene Therapies (TSHA) in Q4 2025: 49 shares worth $270. The stake represents ﹤0.01% of the portfolio and ranks #2499 among its holdings.

195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • SageView Advisory Group held 49 shares of Taysha Gene Therapies worth $270 as of Q4 2025.
  • Taysha Gene Therapies was a new SageView Advisory Group position in Q4 2025.
  • Taysha Gene Therapies made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2499 holding.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.